Blog

Chris Boshoff: Targeted treatment regimen for mCRC with a BRAF V600E mutation

Chris Boshoff/X

Dec 24, 2024, 00:40

Chris Boshoff: Targeted treatment regimen for mCRC with a BRAF V600E mutation

Chris Boshoff, Chief Oncology Officer and Executive Vice President at Pfizer, shared a post on LinkedIn:

“The FDA has granted accelerated approval to our targeted treatment regimen for people with metastatic Colorectal Cancer (mCRC) with a BRAF V600E mutation.

Read the full announcement here.

For more than a decade, Pfizer has been a pioneer in delivering targeted therapies for cancers harboring specific genetic alterations.

Historically, treatment options have been limited and outcomes poor for patients diagnosed with mCRC with BRAF mutations.

In recognition of the significant unmet need, this accelerated approval is one the first in the industry to take place under the FDA’s Project Front Runner, which seeks to support the development and approval of new cancer drugs for advanced or metastatic disease.

As the first and only combination regimen with a BRAF-targeted therapy for this patient population, patients with metastatic CRC who harbor a BRAF V600E mutation now have an urgently needed first-line treatment option.

Congratulations to the entire team on this achievement.”

Chris Boshoff

As Chief Oncology Officer and Executive Vice President at Pfizer, Chris Boshoff leads the company’s Oncology research and development organization. Boshoff, formerly the founding Director of the University College London Cancer Institute, has published over 150 highly cited articles on cancer biology, tumor virology, and experimental cancer medicine. Under his leadership, Pfizer has achieved numerous global approvals for cancer medicines, and has developed various companion diagnostics for precision medicines.

More posts featuring Chris Boshoff.